Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spyre Therapeutics, Inc. (SYRE) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Spyre Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1636282.
Total stock buying since 2016: $12,275,559.
Total stock sales since 2016: $2,258,159.
Total stock option exercises since 2016: $1,683,303.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 18,428 | $299,639 | 0 | $0 |
| 2024 | 0 | $0 | 18,831 | $533,002 | 3,639,680 | $0 |
| 2022 | 597,945 | $796,134 | 0 | $0 | 0 | $0 |
| 2021 | 294,006 | $1,197,316 | 0 | $0 | 0 | $0 |
| 2020 | 165,000 | $783,750 | 0 | $0 | 0 | $0 |
| 2019 | 77,210 | $502,896 | 0 | $0 | 27,021 | $159,018 |
| 2018 | 2,994 | $21,115 | 141,610 | $1,425,518 | 275,107 | $1,524,285 |
| 2017 | 158,668 | $796,374 | 0 | $0 | 0 | $0 |
| 2016 | 819,000 | $8,177,974 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 18,428 | $299,639 | 0 | $0 |
| 2024-10 | 0 | $0 | 300 | $10,929 | 0 | $0 |
| 2024-09 | 0 | $0 | 18,531 | $522,073 | 0 | $0 |
| 2024-04 | 0 | $0 | 0 | $0 | 3,639,680 | $0 |
| 2022-08 | 270,000 | $151,470 | 0 | $0 | 0 | $0 |
| 2022-06 | 28,200 | $20,022 | 0 | $0 | 0 | $0 |
| 2022-03 | 299,745 | $624,642 | 0 | $0 | 0 | $0 |
| 2021-12 | 253,634 | $934,662 | 0 | $0 | 0 | $0 |
| 2021-08 | 40,372 | $262,654 | 0 | $0 | 0 | $0 |
| 2020-04 | 165,000 | $783,750 | 0 | $0 | 0 | $0 |
| 2019-10 | 0 | $0 | 0 | $0 | 18,265 | $107,489 |
| 2019-06 | 31,905 | $196,459 | 0 | $0 | 0 | $0 |
| 2019-05 | 44,586 | $301,334 | 0 | $0 | 0 | $0 |
| 2019-02 | 719 | $5,103 | 0 | $0 | 8,756 | $51,529 |
| 2018-12 | 0 | $0 | 0 | $0 | 171,890 | $909,813 |
| 2018-09 | 0 | $0 | 6,000 | $57,150 | 0 | $0 |
| 2018-08 | 994 | $9,075 | 0 | $0 | 45,833 | $253,934 |
| 2018-07 | 0 | $0 | 0 | $0 | 42,173 | $277,486 |
| 2018-05 | 0 | $0 | 135,610 | $1,368,368 | 0 | $0 |
| 2018-02 | 2,000 | $12,040 | 0 | $0 | 15,211 | $83,052 |
| 2017-12 | 45,409 | $218,996 | 0 | $0 | 0 | $0 |
| 2017-08 | 1,959 | $4,928 | 0 | $0 | 0 | $0 |
| 2017-02 | 111,300 | $572,450 | 0 | $0 | 0 | $0 |
| 2016-08 | 2,000 | $7,974 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Burrows Scott L (Chief Financial Officer) | Sale | 18,428 | 16.26 | 299,639 |
| 2024-10-25 | Albers Jeffrey W. (Director) | Sale | 300 | 36.43 | 10,929 |
| 2024-09-03 | Burrows Scott L (Chief Financial Officer) | Sale | 18,531 | 28.17 | 522,073 |
| 2024-04-25 | Harwin Peter Evan | Option Ex | 3,639,680 | .00 | 0 |
| 2022-08-25 | Souza Marcio (Director) | Buy | 180,000 | .56 | 100,980 |
| 2022-06-08 | Hanley Jr. Michael Conick (Chief Commercial Officer) | Buy | 28,200 | .71 | 20,022 |
| 2022-03-16 | Quinn Anthony G. (President & CEO) | Buy | 80,079 | 2.34 | 187,705 |
| 2022-03-15 | Quinn Anthony G. (President & CEO) | Buy | 42,417 | 1.86 | 78,938 |
| 2022-03-14 | Quinn Anthony G. (President & CEO) | Buy | 67,472 | 1.93 | 130,220 |
| 2022-03-11 | Alspaugh Jonathan (Chief Financial Officer) | Buy | 75,000 | 2.08 | 156,000 |
| 2022-03-11 | Quinn Anthony G. (President & CEO) | Buy | 34,777 | 2.06 | 71,779 |
| 2021-12-13 | Shanafelt Armen (Director) | Buy | 14,685 | 3.65 | 53,600 |
| 2021-12-10 | Shanafelt Armen (Director) | Buy | 13,516 | 3.65 | 49,333 |
| 2021-12-10 | Quinn Anthony G. (President & CEO) | Buy | 10,526 | 3.75 | 39,472 |
| 2021-12-09 | Alspaugh Jonathan (Chief Financial Officer) | Buy | 50,000 | 3.72 | 186,000 |
| 2021-12-09 | Shanafelt Armen (Director) | Buy | 121,799 | 3.67 | 446,758 |
| 2021-12-09 | Quinn Anthony G. (President & CEO) | Buy | 43,108 | 3.70 | 159,499 |
| 2021-08-18 | Alspaugh Jonathan (Chief Financial Officer) | Buy | 7,200 | 6.72 | 48,398 |
| 2021-08-17 | Alspaugh Jonathan (Chief Financial Officer) | Buy | 23,392 | 6.50 | 151,977 |
| 2021-08-16 | Alspaugh Jonathan (Chief Financial Officer) | Buy | 9,780 | 6.37 | 62,279 |
| 2020-04-30 | Quinn Anthony G. (President & CEO) | Buy | 165,000 | 4.75 | 783,750 |
| 2019-10-04 | Quinn Anthony G. (President & CEO) | Option Ex | 18,265 | 5.88 | 107,489 |
| 2019-06-14 | Quinn Anthony G. (President & CEO) | Buy | 5,282 | 6.23 | 32,912 |
| 2019-06-13 | Quinn Anthony G. (President & CEO) | Buy | 14,406 | 6.17 | 88,841 |
| 2019-06-12 | Quinn Anthony G. (President & CEO) | Buy | 12,217 | 6.12 | 74,706 |
| 2019-05-22 | Quinn Anthony G. (President & CEO) | Buy | 3,809 | 6.86 | 26,129 |
| 2019-05-21 | Quinn Anthony G. (President & CEO) | Buy | 13,794 | 6.89 | 94,985 |
| 2019-05-20 | Quinn Anthony G. (President & CEO) | Buy | 8,989 | 6.55 | 58,922 |
| 2019-05-17 | Quinn Anthony G. (President & CEO) | Buy | 6,218 | 6.65 | 41,337 |
| 2019-05-16 | Quinn Anthony G. (President & CEO) | Buy | 5,520 | 6.83 | 37,690 |
| 2019-05-15 | Quinn Anthony G. (President & CEO) | Buy | 6,256 | 6.76 | 42,271 |
| 2019-02-15 | Quinn Anthony G. (President & CEO) | Buy | 719 | 7.10 | 5,103 |
| 2019-02-06 | Quinn Anthony G. (President & CEO) | Option Ex | 8,756 | 5.88 | 51,529 |
| 2018-12-07 | Quinn Anthony G. (President & CEO) | Option Ex | 171,890 | 5.29 | 909,813 |
| 2018-09-27 | Schuchart Aaron (Chief Business Officer) | Sale | 6,000 | 9.53 | 57,150 |
| 2018-08-17 | Schuchart Aaron (Chief Business Officer) | Option Ex | 8,500 | 3.50 | 29,750 |
| 2018-08-15 | Quinn Anthony G. (President & CEO) | Buy | 994 | 9.13 | 9,075 |
| 2018-08-13 | Georgiou George | Option Ex | 37,333 | 6.00 | 224,184 |
| 2018-07-12 | Quinn Anthony G. (Interim CEO) | Option Ex | 38,866 | 6.67 | 259,430 |
| 2018-07-11 | Quinn Anthony G. (Interim CEO) | Option Ex | 3,307 | 5.46 | 18,056 |
| 2018-05-11 | Novartis Ag | Sale | 19,550 | 10.06 | 196,673 |
| 2018-05-10 | Novartis Ag | Sale | 22,725 | 10.13 | 230,204 |
| 2018-05-09 | Novartis Ag | Sale | 51,230 | 10.11 | 517,935 |
| 2018-05-08 | Novartis Ag | Sale | 26,557 | 10.03 | 266,366 |
| 2018-05-07 | Novartis Ag | Sale | 15,548 | 10.11 | 157,190 |
| 2018-02-15 | Quinn Anthony G. (President & CEO) | Buy | 2,000 | 6.02 | 12,040 |
| 2018-02-15 | Quinn Anthony G. (Interim CEO) | Option Ex | 15,211 | 5.46 | 83,052 |
| 2017-12-08 | Quinn Anthony G. (Interim CEO) | Buy | 600 | 5.07 | 3,039 |
| 2017-12-07 | Quinn Anthony G. (Interim CEO) | Buy | 2,800 | 4.99 | 13,966 |
| 2017-12-06 | Quinn Anthony G. (Interim CEO) | Buy | 4,888 | 4.92 | 24,073 |
| 2017-12-05 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 10,241 | 4.75 | 48,695 |
| 2017-12-05 | Quinn Anthony G. | Buy | 5,065 | 4.93 | 24,975 |
| 2017-12-04 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 3,259 | 4.97 | 16,197 |
| 2017-12-04 | Quinn Anthony G. | Buy | 7,956 | 4.98 | 39,620 |
| 2017-12-01 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 6,500 | 4.59 | 29,854 |
| 2017-12-01 | Quinn Anthony G. | Buy | 4,100 | 4.53 | 18,577 |
| 2017-08-15 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 1,959 | 2.52 | 4,928 |
| 2017-02-21 | Isaly Samuel D | Buy | 7,000 | 5.36 | 37,520 |
| 2017-02-17 | Isaly Samuel D | Buy | 71,800 | 5.19 | 372,642 |
| 2017-02-16 | Isaly Samuel D | Buy | 30,500 | 5.04 | 153,720 |
| 2017-02-15 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 2,000 | 4.28 | 8,568 |
| 2016-08-15 | York Charles N Ii (Chief Financial Officer and VP) | Buy | 2,000 | 3.99 | 7,974 |
| 2016-04-12 | Quinn Anthony | Buy | 10,000 | 10.00 | 100,000 |
| 2016-04-12 | Cox Russell J. | Buy | 7,000 | 10.00 | 70,000 |
| 2016-04-12 | Novartis Ag | Buy | 300,000 | 10.00 | 3,000,000 |
| 2016-04-12 | Lilly Eli & Co | Buy | 500,000 | 10.00 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of SYRE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Spyre Therapeutics, Inc. (symbol SYRE, CIK number 1636282) see the Securities and Exchange Commission (SEC) website.